Mayo Clinic Laboratory and Pathology Research Roundup: September 30

By Samantha Rossi • September 30, 2019

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.

Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies including PDAC. Via Clinical Cancer Research.

Read more.

Published to PubMed This Week

• Biliary Amyloidoma as a Cause for Pancreatitis.
  Clinical Gastroenterology Hepatology
• Seasonality of Bartonella henselae IgM and IgG Antibody Positivity Rates.
  Journal of Clinical Microbiology
• Survival Impact of Achieving Minimal Residual Negativity by Multi-Parametric Flow Cytometry in AL Amyloidosis.
  Amyloid

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.